2026-03-10 - MDT - Medtronic Deep Dive

Article published Mar 10, 2026. Prices below use latest available snapshots.

MDT Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium Status: Watching — RSI 36.3 (stale from 02/23), price $98.61, approaching entry zone

Data note: OHLC data last updated 2026-02-23.

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 36.3 (stale — 02/23) — approaching oversold. Price $98.61, -2.0% 30D. SMA20 $100.61. Alert at $92 active.
Moat	Moderate-Wide — scale and switching costs, but execution has lagged peers
Key insight	MDT data is stale (15+ days since 02/23). RSI at 36.3 is above the 30-35 entry trigger. Price at $98.61 is above the $88-94 entry zone. No action until fresh data confirms approach to entry zone. PFA franchise growth and MiniMed spinoff are key catalysts.

Action Matrix

Action	Level	Why
Current	🔍 Watch	RSI 36.3, price above entry zone. Alert at $92. Data stale 15+ days.
Entry Zone	$88 - $94	~10-15% pullback from stale $98.61
Stop-Loss	$79 (-20%)	Below 52-week low ($79.55)
Target 1	$108 (+10%)	Analyst consensus zone
Target 2	$117 (+19%)	All-time high recovery

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
MDT	$98.61	+1.8%	-0.9%	-2.0%	—	-6.5%	36	🟡 Approaching Oversold	🔍 Watch

Note: Data last updated 2026-02-23.

Company Overview

One-Liner

Medtronic is the world's largest standalone medical device company — $34B/year spanning heart rhythm management, surgical robotics, spinal implants, neurostimulation, and diabetes technology.

Key Segments (Q3 FY2026)

Segment	Q3 Revenue	Q3 Organic Growth	Key Products
Cardiovascular	$3.457B	+10.6%	PFA/Affera system, TAVR, cardiac monitoring
Neuroscience	$2.558B	+2.5%	Spinal fusion, neuro-stimulation
Medical Surgical	$2.173B	+2.7%	Hugo surgical robot, endoscopy
Diabetes	$796M	+8.3%	MiniMed CGM, insulin pumps (spinning off mid-2026)

Bull Case

Argument	Evidence	Conviction
PFA is a multi-year growth driver	Cardiac Ablation +80% global, +137% US	🟢 High
MiniMed spinoff unlocks value	Removes GLP-1 narrative; 100+ bps margin uplift	🟢 High
Hugo FDA clearance	Just cleared for urologic procedures Feb 2026	🟡 Medium
Dividend aristocrat	48 years of increases, ~2.9% yield	🟢 High
Cheapest large-cap medtech	P/E ~26x forward vs BSX 57x, SYK 35x	🟢 Medium-High

Bear Case

Argument	Evidence	Risk Level
10-year underperformance	Still 16% below Sept 2021 ATH	🟠 Real
Hugo is years from revenue	ISRG has 10,763+ systems vs Hugo just cleared	🟠 Real
Spine is structural drag	Mature, price-deflationary market	🟡 Medium

Entry Strategy

Strategy	Details
Current	Watch — data stale, RSI above entry trigger
Alert	$92 — entry zone bottom
Entry zone	$88 - $94
RSI target	RSI < 35 with price in $88-94 zone
Stop	$79 (-20%)

Research Log

Date	Update
2026-02-22	Created deep dive. Price ~$97.58. RSI ~58. Q3 FY26 strongest growth in 10 quarters.
2026-02-26	Fresh OHLC. Price $98.61. RSI 36.3. Getting closer to entry zone.
2026-03-03	OHLC stale (02/23). No change. Action: Watch.
2026-03-10	OHLC still stale (02/23) — 15+ days. Action unchanged.

The Gold

Key Discoveries

Discovery	Implication
RSI dropped from ~58 to 36.3	Post-Q3 enthusiasm cooling — approaching entry
SMA20 $100.61, price $98.61	Right at moving average
Data stale 15+ days	Need fresh data for actionable signals

Open Questions

CRITICAL: Current RSI unknown
What are Hugo US placement numbers?
Is Affera winning majority share in new EP labs?
What multiple will MiniMed trade at post-spinoff?

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.